Temporal Profile of Hypofibrinogenemia and Related Coagulation Abnormalities in Patients Receiving Eravacycline: A Retrospective Cohort Study

BACKGROUND: Eravacycline is a novel tetracycline antibiotic approved for complicated intraabdominal infections. Recent reports have suggested a potential association with hypofibrinogenemia, but real-world data are limited. OBJECTIVE: The purpose of this study was to investigate the temporal profile and associated coagulation abnormalities of hypofibrinogenemia in patients receiving eravacycline in a real-world cohort. METHODS: A retrospective observational study was conducted on patients who received eravacycline treatment at a tertiary care center from December 2023 to December 2025. Clinical data of the enrolled patients were collected, and the incidence of hypofibrinogenemia occurring during eravacycline therapy was calculated. The clinical characteristics of patients with hypofibrinogenemia were summarized. RESULTS: Among the 31 patients who received eravacycline for at least 72 h, 7 patients (22.6%) experienced a decline in blood fibrinogen levels (fibrinogen < 2.0 g/L). The median time to the first detected decrease in fibrinogen levels was 4 days, and the median time to nadir was 8 days among affected patients. Fibrinogen decline during eravacycline therapy is frequently accompanied by D-dimer elevation and thrombocytopenia. CONCLUSIONS: There was a temporal association between eravacycline exposure and fibrinogen decline, which was typically observed within the first week of therapy and was frequently accompanied by D-dimer elevation.

Authors

Institutions

Publication Details

Journal
Drugs - Real World Outcomes
Published
2026-11-17
DOI
https://doi.org/10.1007/s40801-026-00580-8
Primary Topic
Blood properties and coagulation
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Temporal Profile of Hypofibrinogenemia and Related Coagulation Abnormalities in Patients Receiving Eravacycline: A Retrospective Cohort Study

Anqi Li, Haiyan Mai, lejia xu, Yanduan Lin et al.
2 links
Drugs - Real World Outcomes
Blood properties and coagulation
article

Temporal Profile of Hypofibrinogenemia and Related Coagulation Abnormalities in Patients Receiving Eravacycline: A Retrospective Cohort Study

Anqi Li, Haiyan Mai, lejia xu, Yanduan Lin, Ye Li, Jing Liu
article en

Abstract

BACKGROUND: Eravacycline is a novel tetracycline antibiotic approved for complicated intraabdominal infections. Recent reports have suggested a potential association with hypofibrinogenemia, but real-world data are limited. OBJECTIVE: The purpose of this study was to investigate the temporal profile and associated coagulation abnormalities of hypofibrinogenemia in patients receiving eravacycline in a real-world cohort. METHODS: A retrospective observational study was conducted on patients who received eravacycline treatment at a tertiary care center from December 2023 to December 2025. Clinical data of the enrolled patients were collected, and the incidence of hypofibrinogenemia occurring during eravacycline therapy was calculated. The clinical characteristics of patients with hypofibrinogenemia were summarized. RESULTS: Among the 31 patients who received eravacycline for at least 72 h, 7 patients (22.6%) experienced a decline in blood fibrinogen levels (fibrinogen < 2.0 g/L). The median time to the first detected decrease in fibrinogen levels was 4 days, and the median time to nadir was 8 days among affected patients. Fibrinogen decline during eravacycline therapy is frequently accompanied by D-dimer elevation and thrombocytopenia. CONCLUSIONS: There was a temporal association between eravacycline exposure and fibrinogen decline, which was typically observed within the first week of therapy and was frequently accompanied by D-dimer elevation.

Drugs - Real World Outcomes
Sun Yat-sen University (CN), Third Affiliated Hospital of Sun Yat-sen University (CN)
Good health and well-being
Blood properties and coagulation
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon